GlassScriptPhysician profile
Sarah Derubeis
NPI 1912208430
$2,316.59
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,793 · 2022: $412 · 2023: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $111.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $337.29 | 2021-2022 | |
| Abbvie INC. | $333.80 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $181.25 | 2021-2022 | |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Lilly USA, LLC | $124.84 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.35 | 2021-2022 | |
| Viiv Healthcare Company | $111.17 | 2023 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.37 | 2021-2022 | |
| Glaxosmithkline, LLC. | $106.41 | 2021-2022 | |
| Amgen INC. | $84.25 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $80.07 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $79.61 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.29 | 2021 | |
| Pfizer INC. | $50.79 | 2021 | |
| Sanofi-Aventis U.S. LLC | $50.70 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $45.71 | 2021 | |
| Pacira Therapeutics, INC. | $33.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.29 | 2021 | |
| Teleflex LLC | $26.61 | 2021 | |
| Alfasigma USA, INC. | $25.91 | 2021-2022 | |
| Lucid Diagnostics INC. | $24.89 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $24.41 | 2021 | |
| Abbott Laboratories | $24.18 | 2021 | |
| Bioventus LLC | $19.39 | 2021 | |
| Depuy Synthes Sales INC. | $18.83 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.06 | 2022 | |
| Allergan, INC. | $17.74 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.82 | 2021 | |
| Eisai INC. | $14.77 | 2021 | |
| Biodelivery Sciences International, INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Derubeis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.